ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/MDM2-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/MDM2-inhibitor
6
trial(s) found.
NCT06479135
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (
POIESIS
)
JAK1/JAK2 inhibitor
MDM2 inhibitor
placebo
Myelofibrosis
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT03787602
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve (
KRT-232-103
)
MDM2 inhibitor
anti-PD-L1 monoclonal antibody
Merkel cell carcinoma
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT03662126
Haem
Phase 2 / Phase 3
Recruiting
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment (
BOREAS
)
MDM2 inhibitor
Myelofibrosis
Polycythemia vera
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
3174 - Noble Park - South Eastern Private Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06058793
Advanced
Phase 3
Not recruiting
Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma (
1403-0019
)
MDM2 inhibitor
Liposarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05512377
Advanced
Phase 2
Active not recruiting
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours (
1403-0011
)
MDM2 inhibitor
Lung adenocarcinoma
NOT Urothelial carcinoma
Urothelial carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05218499
Advanced
Phase 2 / Phase 3
Active not recruiting
Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma (
1403-0008
)
MDM2 inhibitor
anthracycline
Liposarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Glandore - Ashford Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Active not recruiting (2)
Not recruiting (1)
Recruitment Country and State
QLD (5)
VIC (5)
NSW (4)
SA (4)
WA (3)
Phase
Phase 1 / Phase 2 (1)
Phase 2 (1)
Phase 2 / Phase 3 (2)
Phase 3 (2)
Trial Type
Advanced (4)
Haem (2)
Cancer Therapy Class
MDM2
100%
JAK1
17%
JAK2
17%
PD-1/PD-L1
17%
PD-L1
17%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2031 - Randwick - Prince of Wales Hospital (3)
3004 - Melbourne, Southbank - Alfred Health (2)
3168 - Clayton - Monash Medical Centre (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2217 - Kogarah - St George Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
3174 - Noble Park - South Eastern Private Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
5037 - Glandore - Ashford Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Myelofibrosis
Myeloproliferative neoplasm
Liposarcoma
Sarcoma
Soft tissue sarcoma
Merkel cell carcinoma
Non-melanoma skin cancer
Skin cancer
Polycythemia vera
Lung adenocarcinoma
Lung cancer
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
Respiratory tract cancer
Thoracic cancer
Urogenital cancer
Urothelial carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy